Sign In  |  Register  |  About San Anselmo  |  Contact Us

San Anselmo, CA
September 01, 2020 1:33pm
7-Day Forecast | Traffic

  • Search Hotels in San Anselmo

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Ocugen

< Previous 1 2 3 Next >
Ocugen Announces European Medicines Agency Grants Orphan Medicinal Product Designation for Modifier Gene Therapy Candidate OCU410ST for Treatment of ABCA4-Associated Retinopathies including Stargardt Disease
From Ocugen
Via GlobeNewswire
Tickers OCGN
Ocugen Announces Compelling Preliminary Data for OCU410—a Single Dose Novel Modifier Gene Therapy to Treat Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
From Ocugen
Via GlobeNewswire
Tickers OCGN
Ocugen Provides Business Update with Third Quarter 2024 Financial Results
From Ocugen
Via GlobeNewswire
Tickers OCGN
Ocugen Secures $30 Million in Debt Funding
From Ocugen
Via GlobeNewswire
Tickers OCGN
Ocugen Clinical Showcase Highlighting Progress in Retinal Gene Therapy Clinical Trials in New York City on Tuesday, November 12, 2024
From Ocugen
Via GlobeNewswire
Tickers OCGN
Data and Safety Monitoring Board Approves Initiation of Phase 2 of OCU410ST GARDian Clinical Trial for Stargardt Disease
From Ocugen
Via GlobeNewswire
Tickers OCGN
Ocugen to Host Conference Call on Friday, November 8 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2024 Financial Results
From Ocugen
Via GlobeNewswire
Tickers OCGN
Ocugen to Participate in 2024 Maxim Healthcare Virtual Summit
From Ocugen
Via GlobeNewswire
Tickers OCGN
Ocugen, Inc. Announces Removal of Clinical Hold on Investigational New Drug Application for OCU200 Phase 1 Clinical Trial
From Ocugen
Via GlobeNewswire
Tickers OCGN
Ocugen to Present at the 2024 Cell & Gene Meeting on the Mesa
From Ocugen
Via GlobeNewswire
Tickers OCGN
Ocugen to Participate in a Fireside Chat at Chardan’s 8th Annual Genetic Medicines Conference
From Ocugen
Via GlobeNewswire
Tickers OCGN
Ocugen Chairman, CEO & Co-founder, Dr. Shankar Musunuri, to Speak During U.S.-India Initiative on Critical and Emerging Technology Workshop
From Ocugen
Via GlobeNewswire
Tickers OCGN
Ocugen CSO to Participate in 5th Annual Gene Therapy for Ophthalmic Disorders Summit
From Ocugen
Via GlobeNewswire
Tickers OCGN
Ocugen to Participate in a Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference
From Ocugen
Via GlobeNewswire
Tickers OCGN
Ocugen Announces Completion of Dosing in Subjects with Stargardt Disease in High Dose Cohort of Phase 1/2 GARDian Clinical Trial of OCU410ST—A Modifier Gene Therapy
From Ocugen
Via GlobeNewswire
Tickers OCGN
Ocugen, Inc. Announces Health Canada Approval to Initiate Phase 3 Clinical Trial for OCU400 – Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication
From Ocugen
Via GlobeNewswire
Tickers OCGN
Ocugen Provides Business Update with Second Quarter 2024 Financial Results
From Ocugen
Via GlobeNewswire
Tickers OCGN
Ocugen, Inc. Announces FDA Approval of Expanded Access Program for Patients with Retinitis Pigmentosa
From Ocugen
Via GlobeNewswire
Tickers OCGN
Ocugen, Inc. Announces Closing of $35 Million Public Offering of Common Stock
From Ocugen
Via GlobeNewswire
Tickers OCGN
Ocugen, Inc. Announces Pricing of $35 Million Public Offering of Common Stock
From Ocugen
Via GlobeNewswire
Tickers OCGN
Ocugen, Inc. Announces Proposed Public Offering of Common Stock
From Ocugen
Via GlobeNewswire
Tickers OCGN
Ocugen to Host Conference Call on Thursday, August 8 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2024 Financial Results
From Ocugen
Via GlobeNewswire
Tickers OCGN
Ocugen, Inc. Announces Completion of Dosing in Subjects with Geographic Atrophy Secondary to dAMD in High-Dose Cohort of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Novel Modifier Gene Therapy
From Ocugen
Via GlobeNewswire
Tickers OCGN
Ocugen Announces Data and Safety Monitoring Board Approves Enrollment in High Dose Cohort 3 in GARDian Study for Stargardt Disease
From Ocugen
Via GlobeNewswire
Tickers OCGN
Ocugen, Inc. Announces First Patient Dosed in Phase 3 liMeliGhT Clinical Trial for OCU400—First Gene Therapy in Phase 3 with a Broad Retinitis Pigmentosa Indication
From Ocugen
Via GlobeNewswire
Tickers OCGN
Data and Safety Monitoring Board Approves Simultaneous Enrollment in Cohort 3 and Phase 2 Initiation in OCU410 ArMaDa study for Geographic Atrophy
From Ocugen
Via GlobeNewswire
Tickers OCGN
Ocugen to Present at BIO International Convention 2024
From Ocugen
Via GlobeNewswire
Tickers OCGN
Ocugen Set to Join Russell 3000® Index Effective June 28, 2024
From Ocugen
Via GlobeNewswire
Tickers OCGN
Ocugen Announces CSO to Present on Modifier Gene Therapy at International Society for Cell & Gene Therapy 2024
From Ocugen
Via GlobeNewswire
Tickers OCGN
Ocugen Announces Dosing Completion of Subjects with Stargardt Disease in Cohort 2 of Phase 1/2 GARDian Clinical Trial of OCU410ST—A Modifier Gene Therapy
From Ocugen
Via GlobeNewswire
Tickers OCGN
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 SanAnselmo.com & California Media Partners, LLC. All rights reserved.